Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.39 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303948 | 0.88 | NQO2 (0.45) | SERPINE1CTSKCTSBCTSSNAMPT | |
| SCHEMBL30504293 | 0.87 | HDAC1 (0.56) | BRD4CREBBPHDAC1GLSCTSK | |
| SCHEMBL2569299 | 0.85 | HDAC1 (0.49) | HDAC1CTSKCTSSNAMPT | |
| SCHEMBL18664426 | 0.84 | HDAC1 (0.60) | BRD4CREBBPHDAC1GLSCTSK | |
| SCHEMBL16410240 | 0.83 | BRD4 (0.53) | BRD4CREBBPHDAC1GLSCTSK | |
| SCHEMBL2572109 | 0.82 | HDAC1 (0.52) | BRD4CREBBPHDAC1GLSCTSK | |
| SCHEMBL16410438 | 0.81 | BRD4 (0.51) | BRD4CREBBPHDAC1GLSCTSK | |
| SCHEMBL2568359 | 0.81 | HDAC1 (0.56) | BRD4CREBBPHDAC1GLSCTSK | |
| SCHEMBL1016234 | 0.81 | PRMT6 (0.58) | BRD4CREBBPHDAC1GLSCTSK | |
| SCHEMBL28275382 | 0.80 | SERPINE1 (0.47) | SERPINE1HDAC1AOC3PADI3PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415479-B2 | Inhibitor of plasminogen activator inhibitor-1 | RENASCIENCE CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | SERPINE1 1066/4885BRD4 358/4885CREBBP 3495/4885 |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | SERPINE1, SERPINB1, SERPINC1 | SERPINE1 1/4885BRD4 2049/4885CREBBP 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.